BMAL1 and colorectal carcinoma: Finally, BMAL1 SNPs (rs7396943, rs7938307, rs2279287) were correlated with poorer PFS and OS, and high BMAL1 expression in tumor cells was correlated with unfavorable clinical outcomes in bevacizumab-treated CRC patients [52].